Metabolomics as an Extension of Proteomic Analysis: Study of Acute Kidney Injury

Seminars in Nephrology

Volumn 27, Issue 6, 2007, Pages 609-620

  Portilla, Didier ^a   Schnackenberg, Laura ^b   Beger, Richard D ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

acute kidney injury; cisplatin; mass spectrometry; Metabolomics; nuclear magnetic resonance

Indexed keywords

AMINO ACID; CISPLATIN; FATTY ACID; GLUCOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIRINIXIC ACID; TRIACYLGLYCEROL; TRICHLOROACETIC ACID;

ARTICLE; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVITY; GLUCOSURIA; KIDNEY INJURY; MASS SPECTROMETRY; METABOLOMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; PROTON NUCLEAR MAGNETIC RESONANCE; SINGLE DRUG DOSE; STUDENT T TEST;

CISPLATIN; FATTY ACIDS; GLUCOSE; HUMANS; HYPERGLYCEMIA; INSULIN; KIDNEY; KIDNEY FAILURE, ACUTE; MAGNETIC RESONANCE SPECTROSCOPY; PPAR ALPHA; PROTEINS; PROTEOMICS; TRIGLYCERIDES;

EID: 36549029196     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2007.09.006     Document Type: Article

References (42)

1. Vaidya V.S., and Bonventre J.V. Mechanistic biomarkers for cytotoxic acute kidney injury. Expert Opin Drug Metab Toxicol 2 (2006) 697-713
2. Fiehn O. Metabolomics-the link between genotypes and phenotypes. Plant Mol Biol 48 (2002) 155-171
3. Nicholson J.K., Lindon J.C., and Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29 (1999) 1181-1189
4. Raamsdonk L.M., Teusink B., Broadhurst D., Zhang N., Hayes A., Walsh M.C., et al. A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat Biotechnol 19 (2001) 45-50
5. Robertson D.G., Reily M.D., Sigler R.E., Wells D.F., Paterson D.A., and Braden T.K. Metabonomics: evaluation of nuclear magnetic resonance (NMR) and pattern recognition technology for rapid in vivo screening of liver and kidney toxicants. Toxicol Sci 57 (2000) 326-337
6. Williams R.E., Jacobsen M., and Lock E.A. 1H NMR pattern recognition and 31P NMR studies with D-serine in rat urine and kidney, time- and dose-related metabolic effects. Chem Res Toxicol 16 (2003) 1207-1216
7. Lenz E.M., Bright J., Knight R., Westwood F.R., Davies D., Major H., et al. Metabonomics with 1H-NMR spectroscopy and liquid chromatography-mass spectrometry applied to the investigation of metabolic changes caused by gentamicin-induced nephrotoxicity in the rat. Biomarkers 10 (2005) 173-187
8. Serkova N., Fuller T.F., Klawitter J., Freise C.E., and Niemann C.U. H-NMR based metabolic signatures of mild and severe ischemia/reperfusion injury in rat kidney transplants. Kidney Int 67 (2005) 1142-1151
9. Portilla D., Li S., Nagothu K., Megyesi J., Schnackenberg L., Safirstein R.L., et al. Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int 69 (2006) 2194-2204
10. Schnackenberg L.K., Dragan Y.P., Reily M.D., Robertson D.G., and Beger R.D. Evaluation of NMR spectral data of urine in conjunction with measured clinical chemistry and histopathology parameters to assess the effects of liver and kidney toxicants. Metabolomics 3 (2007) 87-100
11. Coen M., Lenz E.M., Nicholson J.K., Wilson I.D., Pognan F., and Lindon J.C. An integrated metabonomic investigation of acetaminophen toxicity in the mouse using NMR spectroscopy. Chem Res Toxicol 16 (2003) 295-303
12. Schnackenberg L., Beger R.D., and Dragan Y. NMR-based metabonomic evaluation of livers from rats chronically treated with tamoxifen, mestranol, and phenobarbital. Metabonomics 1 (2005) 87-94
13. Waters N.J., Waterfield C.J., Farrant R.D., Holmes E., and Nicholson J.K. Integrated metabonomic analysis of bromobenzene-induced hepatotoxicity: novel induction of 5-oxoprolinosis. J Proteome Res 5 (2006) 1448-1459
14. Serkova N., Fuller T.F., Klawitter J., Freise C.E., and Niemann C.U. H-NMR-based metabolic signatures of mild and severe ischemia/reperfusion injury in rat kidney transplants. Kidney Int 67 (2005) 1142-1151
15. Odunsi K., Wollman R.M., Ambrosone C.B., Hutson A., McCann S.E., Tammela J., et al. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int J Cancer 113 (2005) 782-788
16. Beger R.D., Schnackenberg L.K., Li D., and Dragan Y. Metabonomic models of human pancreatic cancer using 1D proton NMR spectra of lipids in plasma. Metabolomics 2 (2006) 125-134
17. Brindle J.T., Antti H., Holmes E., Tranter G., Nicholson J.K., Bethel H.W.L., et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med 8 (2002) 1439-1445
18. Mayr M., Chung Y.L., Mayr U., Yin X., Ly L., Troy H., et al. Proteomic and metabolomic analyses of atherosclerotic vessels from apolipoprotein E-deficient mice reveal alterations in inflammation, oxidative stress, and energy metabolism. Arterioscler Thromb Vasc Biol 25 (2005) 2135-2142
19. Naziroglu M., Karaoglu A., and Aksoy A.O. Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology 195 (2004) 221-230
20. Price P.M., Safirstein R.L., and Megyesi J. Protection of renal cells from cisplatin toxicity by cell cycle inhibitors. Am J Physiol 286 (2004) F378-F384
21. Atasoyu E.M., Yildiz S., Bilgi O., Cermik H., Evrenkaya R., Aktas S., et al. Investigation of the role of hyperbaric oxygen therapy in cisplatin-induced nephrotoxicity in rats. Arch Toxicol 79 (2005) 289-293
22. Santos N.A., Catao C.S., Martins N.M., Curti C., Bianchi M.L., and Santos A.C. Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch Toxicol 81 (2007) 495-504
23. Delaney J., Hodson M.P., Thakkar H., Connor S.C., Sweatman B.C., Kenny S.P., et al. Tryptophan-NAD+ pathway metabolites as putative biomarkers and predictors of peroxisome proliferation. Arch Toxicol 79 (2005) 208-223
24. Li S., Wu P., Yarlagadda P., Vadjunec N.M., Proia A.D., Harris R.A., et al. PPAR alpha ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity. Am J Physiol 286 (2004) F572-F580
25. Chinetti-Gbaguidi G., Fruchart J.C., and Staels B. Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy. Curr Opin Pharmacol 5 (2005) 177-183
26. Lenz E.M., Bright J., Knight R., Wilson I.D., and Major H. A metabonomic investigation of the biochemical effects of mercuric chloride in the rat using 1H NMR and HPLC-TOF/MS: time dependent changes in the urinary profile of endogenous metabolites as a result of nephrotoxicity. Analyst 129 (2004) 535-541
27. Fleck C., Schwertfeger M., and Taylor P.M. Regulation of renal amino acid (AA) transport by hormones, drugs and xenobiotics-a review. Amino Acids 24 (2003) 347-374
28. Fleck C., Kretzschel I., Sperschneider T., and Appenroth D. Renal amino acid transport in immature and adult rats during chromate and cisplatinum-induced nephrotoxicity. Amino Acids 20 (2001) 201-215
29. Takamoto K., Kawada M., Usui T., Ishizuka M., and Ikeda D. Aminoglycoside antibiotics reduce glucose reabsorption in kidney through down-regulation of SGLT1. Biochem Biophys Res Commun 308 (2003) 866-871
30. Goldstein R.S., Mayor G.H., Rosenbaum R.W., Hook J.B., Santiago J.V., and Bond J.T. Glucose intolerance following cis-platinum treatment in rats. Toxicology 24 (1982) 273-280
31. Goldstein R.S., Mayor G.H., Gingerich R.L., Hook J.B., Rosenbaum R.W., and Bond J.T. The effects of cisplatin and other divalent platinum compounds on glucose metabolism and pancreatic endocrine function. Toxicol Appl Pharmacol 69 (1983) 432-441
32. Jia D., and Otsuki M. Bezafibrate, a peroxisome proliferator-activated receptor (PPAR)-alpha activator, prevents pancreatic degeneration in obese and diabetic rats. Pancreas 26 (2003) 286-291
33. Koh E.H., Kim M.S., Park J.Y., Kim H.S., Youn J.Y., Park H.S., et al. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation. Diabetes 52 (2003) 2331-2337
34. Bihan H., Rouault C., Reach G., Poitout V., Staels B., and Guerre-Millo M. Pancreatic islet response to hyperglycemia is dependent on peroxisome proliferator-activated receptor alpha (PPARalpha). FEBS Lett 579 (2005) 2284-2288
35. Nagothu K.K., Bhatt R., Kaushal G.P., and Portilla D. Fibrate prevents cisplatin-induced proximal tubule cell death. Kidney Int 68 (2005) 2680-2693
36. Abdel-Gayoum A.A., El-Jenjan K.B., and Ghwarsha K.A. Hyperlipidaemia in cisplatin-induced nephrotic rats. Hum Exp Toxicol 18 (1999) 454-459
37. Staels B., Vu-Dac N., Kosykh V.A., Saladin R., Fruchart J.C., Dallongeville J., et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 95 (1995) 705-712
38. van Dijk K.W., Rensen P.C., Voshol P.J., and Havekes L.M. The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism?. Curr Opin Lipidol 15 (2004) 239-246
39. Peters J.M., Hennuyer N., Staels B., Fruchart J.C., Fievet C., Gonzalez F.J., et al. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem 272 (1997) 27307-27312
40. Schnackenberg L.K., Jones R.C., Thyparambil S., Taylor J.T., Han T., Tong W., et al. An integrated study of acute effects of valproic acid in the liver using metabonomics, proteomics, and transcriptomics platforms. OMICS 10 (2006) 1-14
41. Edmonson R.D., Vondriska T.M., Biederman K.J., Zhang J., Jones R.C., Zheng Y., et al. Protein kinase C epsilon signaling complexes include metabolism- and transcription/translation-related proteins: complimentary separation techniques with LC/MS/MS. Mol Cell Proteomics 1 (2002) 421-433
42. Gambus A., Jones R.C., Sanchez-Diaz A., Kanemaki M., van Deursen F., Edmonson R.D., et al. GINS-dependent replisome progression complex controls the advance of eukaryotic DNA replication forks. Nat Cell Biol 8 (2006) 358-366